Kevin H M Kuo

List of Publications by Year
in descending order

58	696	758635 12	580395 25
papers	citations	h-index	g-index

58	58	58	946
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Advances, 2022, 6, 1844-1853.	2.5	12
2	Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. Journal of Clinical Medicine, 2022, 11, 1193.	1.0	4
3	Assessing Cerebrovascular Resistance in Patients With Sickle Cell Disease. Frontiers in Physiology, 2022, 13, 847969.	1.3	3
4	The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096.	1.2	15
5	Adverse outcome of acute splenic sequestration crisis in pregnancy. Obstetric Medicine, 2021, 14, 113-115.	0.5	0
6	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	1.1	17
7	Screening for Cognitive Dysfunction Using the Rowland Universal Dementia Assessment Scale in Adults With Sickle Cell Disease. JAMA Network Open, 2021, 4, e217039.	2.8	7
8	Comparison of Inline R2* MRI versus FerriScan for liver iron quantification in patients on chelation therapy for iron overload: preliminary results. European Radiology, 2021, 31, 9296-9305.	2.3	5
9	Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. British Journal of Haematology, 2021, 194, 1063-1073.	1.2	10
10	The International Hemoglobinopathy Research Network (<scp>INHERENT</scp>): An international initiative to study the role of genetic modifiers in hemoglobinopathies. American Journal of Hematology, 2021, 96, E416-E420.	2.0	14
11	Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency. Blood, 2021, 138, 2005-2005.	0.6	3
12	Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Blood, 2021, 138, 576-576.	0.6	5
13	Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat. Blood, 2021, 138, 924-924.	0.6	3
14	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell Disease. Blood, 2021, 138, 3109-3109.	0.6	2
15	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. Blood, 2021, 138, 3074-3074.	0.6	0
16	Cognitive Profile of Adults with Sickle Cell Disease - Cluster Analysis. Blood, 2021, 138, 3120-3120.	0.6	1
17	Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers. Blood, 2021, 138, 4173-4173.	0.6	1
18	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	2.0	8

#	Article	IF	Citations
19	Novel High Oxygen Affinity Hemoglobin Variant in a Patient with Polycythemia: Hb Kennisis [Î²85(F1)Pheâ†'Leu (TTT>TTG); HBB: c.258T>G]. Hemoglobin, 2020, 44, 10-12.	0.4	2
20	Genotypeâ€phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	2.0	47
21	Impact of MRI technique on clinical decision-making in patients with liver iron overload: comparison of FerriScan- versus R2*-derived liver iron concentration. European Radiology, 2020, 30, 1959-1968.	2.3	4
22	The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica, 2020, 105, 2229-2239.	1.7	30
23	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	0.6	8
24	Sickle Cell Cerebrovascular Reactivity to a CO2 Stimulus Is Both Too Little and Too Slow. Blood, 2020, 136, 55-55.	0.6	1
25	Evidence of Educational Bias in Cognitive Screening of Adults with Sickle Cell Disease: Comparison of Available Tools and Possible Strategies for Mitigation. Blood, 2020, 136, 13-14.	0.6	2
26	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. Blood, 2020, 136, 30-32.	0.6	3
27	Characterizing the Process of Urgent Referrals and Transfers to a Large Tertiary Care Apheresis Centre in Ontario. Blood, 2020, 136, 28-28.	0.6	0
28	Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review. Blood, 2020, 136, 11-12.	0.6	0
29	Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfusion Medicine Reviews, 2019, 33, 256-265.	0.9	46
30	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. New England Journal of Medicine, 2019, 381, 933-944.	13.9	115
31	Impact of a transition program with navigator on loss to followâ€up, medication adherence, and appointment attendance in hemoglobinopathies. Pediatric Blood and Cancer, 2019, 66, e27781.	0.8	33
32	Deferiprone exerts a doseâ€dependent reduction of liver iron in adults with iron overload. European Journal of Haematology, 2019, 103, 80-87.	1.1	14
33	Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e37-e42.	0.2	2
34	Cord gas parameters in infants born to women with sickle cell disease: a retrospective matched cohort study. British Journal of Haematology, 2019, 184, 653-657.	1.2	3
35	Patient Education Interventions for Improving Self-Management in Adults with Hemoglobinopathies: A Systematic Review and Meta-Analysis. Blood, 2019, 134, 5783-5783.	0.6	0
36	A proposed treatment algorithm for adults with Haemoglobin <scp>SC</scp> disease. British Journal of Haematology, 2018, 182, 607-609.	1.2	11

#	Article	IF	Citations
37	Approach to transfusion in pregnant women with sickle cell disease: a survey of physicians. British Journal of Haematology, 2018, 183, 516-519.	1.2	3
38	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	0.6	11
39	Should Women with Sickle Cell Disease be Administered Prophylactic Transfusions to Avoid Complications during Pregnancy?. Blood, 2018, 132, 3679-3679.	0.6	0
40	Validation of Sickle Cell Disease Severity Score in a Cohort of Hemoglobin SC Disease Patients. Blood, 2018, 132, 2287-2287.	0.6	0
41	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	2.0	10
42	Multiple Testing in the Context of Gene Discovery in Sickle Cell Disease Using Genome-Wide Association Studies. Genomics Insights, 2017, 10, 117863101772117.	3.0	11
43	EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis. PLoS ONE, 2016, 11, e0149830.	1.1	2
44	Extracorporeal photopheresis in solid organ transplantâ€“associated acute graftâ€versusâ€host disease. Transfusion, 2016, 56, 962-969.	0.8	12
45	Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study. Blood, 2016, 128, 402-402.	0.6	5
46	Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood, 2015, 126, 2424-2435.	0.6	81
47	A comparison of chronic manual and automated red blood cell exchange transfusion in sickle cell disease patients. British Journal of Haematology, 2015, 170, 425-428.	1.2	38
48	A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. British Journal of Haematology, 2015, 168, 384-394.	1.2	36
49	Optimal Manual Exchange Transfusion Protocol for Sickle Cell Disease: A Retrospective Comparison of Two Comprehensive Care Centers in the United Kingdom and Canada. Hemoglobin, 2015, 39, 310-315.	0.4	5
50	A Systematic Review and Meta-Analysis of Deferiprone Monotherapy and in Combination with Deferoxamine for Reduction of Iron Overload in Chronically Transfused Patients with Î²-Thalassemia. Hemoglobin, 2014, 38, 409-421.	0.4	37
51	A North American Experience Of Hemoglobin SC Disease, Its Complications, and Management. Blood, 2013, 122, 2221-2221.	0.6	2
52	Characterization Of Pulmonary Compliance In Sickle Cell Patients Revealed Wide Variability. Blood, 2013, 122, 989-989.	0.6	0
53	Treatment Patterns and Outcomes Of Sickle Cell Patients With Frequent ER Visits: A Single Center Experience. Blood, 2013, 122, 1010-1010.	0.6	1
54	Effectiveness Of An Analgesia Protocol For The Treatment Of Painful Vaso-Occlusive Crisis Of Sickle Cell Disease Patients In Emergency Room: A Retrospective Cohort Study. Blood, 2013, 122, 2222-2222.	0.6	1

#	Article	IF	Citations
55	A Comparison of Automated Red Blood Cell Depletion/Exchange to Automated Red Cell Blood Exchange in Sickle Cell Patients.. Blood, 2012, 120, 2281-2281.	0.6	2
56	A Comparison of Chronic Manual and Automated Red Blood Cell Exchange Transfusion in Sickle Cell Disease Patients From Two Comprehensive Care Centres in the United Kingdom. Blood, 2012, 120, 3430-3430.	0.6	1
57	The Effect of Comprehensive Care on Maternal and Fetal Outcomes in Sickle Cell Disease Pregnancies. Blood, 2011, 118, 4842-4842.	0.6	0
58	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.. Blood, 2006, 108, 2007-2007.	0.6	7